CC
CRSP icon

Corton Capital’s CRISPR Therapeutics CRSP Stock Holding History

Corton Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,179
Closed -$421K – 548
2024
Q1 		$421K Sell
6,179
-932
-13% -$66.7K 0.16% 175
2023
Q4 		$445K Buy
7,111
+1,702
+31% +$94.1K 0.14% 196
2023
Q3 		$246K Buy
5,409
+313
+6% +$16.2K 0.12% 248
2023
Q2 		$286K Buy
5,096
+214
+4% +$12.1K 0.13% 226
2023
Q1 		$221K Sell
4,882
-619
-11% -$30.1K 0.15% 215
2022
Q4 		$224K Buy
+5,501
New +$292K 0.18% 192
2022
Q2 		– Sell
-3,586
Closed -$225K – 367
2022
Q1 		$225K Buy
+3,586
New +$225K 0.1% 328

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Corton Capital's CRSP Position: Q2 2024 in Review

Corton Capital sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 6,179 shares — an estimated $421K sold.

Corton Capital first reported a position in CRSP in Q1 2022 and held it in 7 quarters. The position peaked at $445K in Q4 2023. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Corton Capital reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Corton Capital sold 6,179 CRISPR Therapeutics shares in Q2 2024, an estimated $421K.
  • Corton Capital first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 7 quarters.
  • Corton Capital's CRISPR Therapeutics position peaked at $445K in Q4 2023.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Corton Capital's 13F filing for Q2 2024, filed 14 Aug 2024.